WallStreetZenWallStreetZen

NASDAQ: NMRA
Neumora Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for NMRA

Based on 5 analysts offering 12 month price targets for Neumora Therapeutics Inc.
Min Forecast
$18.00+3.57%
Avg Forecast
$22.00+26.58%
Max Forecast
$26.00+49.6%

Should I buy or sell NMRA stock?

Based on 5 analysts offering ratings for Neumora Therapeutics Inc.
Strong Buy
Strong Buy
4 analysts 80%
Buy
1 analysts 20%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NMRA stock forecasts and price targets.

NMRA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-11-08
lockedlocked$00.00+00.00%2023-10-10
lockedlocked$00.00+00.00%2023-10-10
lockedlocked$00.00+00.00%2023-10-10
lockedlocked$00.00+00.00%2023-10-10

1 of 1

Forecast return on equity

Is NMRA forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is NMRA forecast to generate an efficient return on assets?
Insufficient data to display

NMRA revenue forecast

What is NMRA's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$16.7M
Avg 2 year Forecast
$157.6M
Avg 3 year Forecast
$437.2M

NMRA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NMRA$17.38$22.00+26.58%Strong Buy
KYMR$42.60$40.25-5.52%Buy
RCKT$28.71$55.83+94.47%Strong Buy
DNA$1.26$2.20+74.60%Hold
TGTX$17.87$27.50+53.89%Strong Buy

Neumora Therapeutics Stock Forecast FAQ

Is Neumora Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: NMRA) stock is to Strong Buy NMRA stock.

Out of 5 analysts, 4 (80%) are recommending NMRA as a Strong Buy, 1 (20%) are recommending NMRA as a Buy, 0 (0%) are recommending NMRA as a Hold, 0 (0%) are recommending NMRA as a Sell, and 0 (0%) are recommending NMRA as a Strong Sell.

If you're new to stock investing, here's how to buy Neumora Therapeutics stock.

What is NMRA's revenue growth forecast for 2026-2028?

(NASDAQ: NMRA) Neumora Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.84%.

Neumora Therapeutics's revenue in 2024 is N/A.On average, 2 Wall Street analysts forecast NMRA's revenue for 2026 to be $2,550,603,487, with the lowest NMRA revenue forecast at $1,773,801,719, and the highest NMRA revenue forecast at $3,327,405,256. On average, 2 Wall Street analysts forecast NMRA's revenue for 2027 to be $24,071,692,624, with the lowest NMRA revenue forecast at $16,952,358,626, and the highest NMRA revenue forecast at $31,191,179,326.

In 2028, NMRA is forecast to generate $66,764,943,822 in revenue, with the lowest revenue forecast at $66,764,943,822 and the highest revenue forecast at $66,764,943,822.

What is NMRA's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: NMRA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is NMRA's Price Target?

According to 5 Wall Street analysts that have issued a 1 year NMRA price target, the average NMRA price target is $22.00, with the highest NMRA stock price forecast at $26.00 and the lowest NMRA stock price forecast at $18.00.

On average, Wall Street analysts predict that Neumora Therapeutics's share price could reach $22.00 by Nov 8, 2024. The average Neumora Therapeutics stock price prediction forecasts a potential upside of 26.58% from the current NMRA share price of $17.38.

What is NMRA's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: NMRA) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.